Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Cardiol Therapeutics Inc. CRDL


Primary Symbol: T.CRDL Alternate Symbol(s):  T.CRDL.W.A

Cardiol Therapeutics’ lead product, CardiolRx™, is an oral pharmaceutical that is currently being evaluated in the Phase II multi-national ARCHER trial in patients presenting with acute myocarditis. Cardiol has received IND authorization from the FDA to conduct a clinical study to evaluate CardiolRx™ in a Phase II multi-center open-label pilot study in recurrent pericarditis. Cardiol is developing a subcutaneously administered drug formulation of cannabidiol intended for use in heart failure.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

Peeps liked the filing

The boys is doing it, https://quantisnow.com/insight/3668667 https://www.youtube.com/watch?v=bQDC_wuJ6j0&ab_channel=TBILISELICOLCHI  rate and reply

RE:0.68cents wild

Never say never Hun: https://online-calculator.org/stock-average-calculator.aspx  rate and reply

Leading Psychedelic Co. Reports 643% Year-Over-Year Revenue Growth

"...gross profit grew 628% to $1.3 million. We're excited about the momentum building across our business and the regulatory reform underway across the US and Canada, and will continue to evaluate complementary growth opportunities that will enhance our client experience and further support margin expansion ...read more

0.68cents wild

sorry for the folks that bought shares at 4 bucks. Seems like alot of people lost money on this one  rate and reply

RE:Bought more Cardiol today

I can't resist,, Jordan you pumper, September October has come and gone  rate and reply

Bought more Cardiol today

Couldn't resist. September is coming. Bounce incoming   rate and reply

I’m back! Party coming soon?

I think once everyone gets back to work end of August into September, we will see a surge in the price of our shares. I bought more here last week. I am very hopeful what cardio will be able to do if...read more

RE:RE:This will recover. Hang tight IMHO

No pump here, I just like the company and what they are doing. I see the potential. Hope you're not shorting this as you may find yourself covering at much higher share price levels. Get positive...read more

RE:This will recover. Hang tight IMHO

Yup.. keep on pumping,,,,    rate and reply

Thematica Insights Report and Investor Guide

Thematica Report: Investing in undervalued stocks

The Market Herald launches Thematica's latest report: Unlocking the Advantages of Undervalued Stocks. Download it today!

This will recover. Hang tight IMHO

When the dust settles, Cardiol Therapeutics will pop again back towards the $3.00 level. Still undervalued at that level in my opinion. Company is quiet until the markets settle down. Great management...read more

Where is everybody?

I think it's really wise here to do some homework on this company. I've been following them for a long time and have not sold a single share. I'm looking forward to hearing how the phase 2...read more

New Press Release - Cardiol Therapeutics Announces At-The-Market Equity Offering Program

Oakville, Ontario--(Newsfile Corp. - June 9, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of...read article.

RE:RE:RE:Geez

Agreed - the $50M looks to be the catalsy for share price drop. Although, as a micro-biotech company I would say this turned out to be a positive looking back. Trying to raise $50M in these markets...read more

RE:RE:Im buying the dip

boilerroom stooge ..not letting you work from home ? Lol  rate and reply

New Press Release - Market Movers. Today's Top Stock Picks For New & Trending Opportunities

Market Movers. Today's Top Stock Picks For New & Trending OpportunitiesVANCOUVER, BC / ACCESSWIRE / May 27, 2022 / Investors want insight. Welcome to the Market Movers Newsletter where we have created a snapshot of new and trending companies that we think investors will want to know about. Below...read article.

RE:Im buying the dip

still Pumping Jordan? I think you said this almost a year and a half ago LOL  rate and reply

Im buying the dip

Nice that we are able to nibble away on some Cardiol stock below $1.75. I think if we all hold here long enough, brighter days will follow. Their bio-technology efforts could be rewarded handsomely...read more

RE:RE:RE:Picked up a few more shares

GW is definately ahead in respect to EPI...cant help but wonder if CRDL gets orphan designation for acute myocarditis, larger addressible market. Even if pharma scoops this up for $1B thats 10x today....read more

RE:RE:Picked up a few more shares

I can't see this one surviving. CBD is everywhere and GW pharma which produces pharma grade CBD is way ahead of them. Don't listen to analysts, you can lose a lot of money. I remember this one...read more

RE:Picked up a few more shares

Its on the run im picking up shares  rate and reply

Picked up a few more shares

Can't resist. Anything below two dollars I think as a gift to us. Just waiting to hear about phase 2. The markets have been rocked but the potential here outweighs much of the noise. Looking...read more